 | |
| Species: |
Dog |
| Strain/breeder: |
Beagle / Marshall |
| Sex: |
Male (8A), female (8B) |
| Age: |
12-14 Months |
| Study type: |
Oral, 4 weeks treatment |
| Treatment: |
Anticancer compound, high dose |
| Animal status: |
Scheduled sacrifice: 8A: after 4 weeks treatment
8B: after an additional 6-week recovery period
|
| Clinical findings: |
Salivation, vomiting, body weight loss, anemia, leukopenia, increased liver enzymes |
| Organ(s): |
Liver |
Macroscopic finding(s): |
None |
| Staining: |
H&E |
|
 |
 Fig. 1 (130k)
 Fig. 2 (132k)
|
|